AgingResearch.NewsJoin free

The Catholic University of Korea, Seoul St. Mary's Hospital

CompanySouth Korea

The Catholic University of Korea, Seoul St. Mary's Hospital develops one asset, in phase 2 (PG-102 in type 2 diabetes). Mostly other acting on GLP1R and GLP2R; based in South Korea.

1
Asset
Furthest stage
Phase 2
2
Trials
2
Signals

Pipeline

1

  • PG-102

    Activates GLP-1 and GLP-2 receptors through a bispecific Fc fusion protein to improve glycemic control.

    Phase 2, Other, GLP1R, GLP2R, type 2 diabetes

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms3
  • Trials2
  • Signals2
  • Similar companies6

Intelligence